SWTX SpringWorks Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

SWTX [NASD]

SpringWorks Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.60	Insider Own	15.58%	Shs Outstand	41.95M	Perf Week	-3.44%
Market Cap	1.84B	Forward P/E	-	EPS next Y	-2.30	Insider Trans	0.00%	Shs Float	32.80M	Perf Month	-0.02%
Income	-68.20M	PEG	-	EPS next Q	-0.48	Inst Own	81.70%	Short Float	6.97%	Perf Quarter	0.92%
Sales	-	P/S	-	EPS this Y	-176.60%	Inst Trans	5.86%	Short Ratio	9.36	Perf Half Y	49.14%
Book/sh	6.93	P/B	6.49	EPS next Y	-25.10%	ROA	-21.00%	Target Price	54.40	Perf Year	87.68%
Cash/sh	7.11	P/C	6.32	EPS next 5Y	-	ROE	-21.70%	52W Range	17.02 - 53.63	Perf YTD	16.78%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-16.18%	Beta	-
Dividend %	-	Quick Ratio	30.80	Sales past 5Y	-	Gross Margin	-	52W Low	164.10%	ATR	3.80
Employees	56	Current Ratio	30.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	50.68	Volatility	8.74% 9.11%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-13.30%	Profit Margin	-	Rel Volume	1.08	Prev Close	48.21
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	244.22K	Price	44.95
Recom	2.00	SMA20	1.12%	SMA50	4.79%	SMA200	23.28%	Volume	264,039	Change	-6.76%

May-05-20

Initiated

Barclays

Overweight

$48

Mar-19-20

Upgrade

H.C. Wainwright

Neutral → Buy

$40 → $60

Mar-04-20

Downgrade

H.C. Wainwright

Buy → Neutral

$40

Jan-21-20

Reiterated

H.C. Wainwright

Buy

$34 → $40

Dec-04-19

Initiated

H.C. Wainwright

Buy

Oct-08-19

Initiated

Wedbush

Outperform

$33

Oct-08-19

Initiated

JP Morgan

Overweight

$32

Oct-08-19

Initiated

Goldman

Buy

$37

Oct-08-19

Initiated

Cowen

Outperform

Sep-22-20 04:05PM	SpringWorks Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference GlobeNewswire +7.46%
Sep-21-20 07:00AM	Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma GlobeNewswire
Sep-18-20 06:30AM	SpringWorks Therapeutics Enters into Sponsored Research Agreement with Fred Hutchinson Cancer Research Center to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma GlobeNewswire +5.03%
Sep-16-20 06:30AM	SpringWorks Therapeutics Announces Collaboration with Childrens Oncology Group to Conduct a Phase 2 Clinical Trial of Nirogacestat in Pediatric Patients with Desmoid Tumors and Reports Publication of Nirogacestat Case Series in Pediatric/Young Adult Desmoid Tumor Patients GlobeNewswire +8.93%
Sep-14-20 06:30AM	SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma GlobeNewswire +11.60%
Aug-12-20 04:45PM	SpringWorks Therapeutics Reports Second Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire -5.84%
Aug-04-20 06:30AM	SpringWorks Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-22-20 06:30AM	SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors GlobeNewswire
Jun-28-20 04:53PM	Hedge Funds Keep Buying SpringWorks Therapeutics, Inc. (SWTX) Insider Monkey
Jun-22-20 09:00AM	BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial GlobeNewswire
06:30AM	SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and GlaxoSmithKlines Belantamab Mafodotin for the Treatment of Relapsed or Refractory Multiple Myeloma GlobeNewswire
Jun-17-20 08:30AM	SpringWorks Therapeutics (SWTX) in Focus: Stock Moves 5.9% Higher Zacks
Jun-10-20 06:14AM	SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Good Position To Deliver On Growth Plans Simply Wall St. +5.59%
Jun-02-20 06:30AM	SpringWorks Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference GlobeNewswire +5.21%
May-26-20 06:30AM	SpringWorks Therapeutics Appoints Julie Hambleton, M.D. to its Board of Directors GlobeNewswire
May-12-20 07:30AM	SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights GlobeNewswire +7.34%
Apr-15-20 02:49PM	Hedge Funds Have Never Been More Bullish On SpringWorks Therapeutics, Inc. (SWTX) Insider Monkey -10.01%
Mar-18-20 06:30AM	SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 GlobeNewswire
Mar-12-20 04:30PM	SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights GlobeNewswire -13.45%
Feb-27-20 07:14AM	MapKure, BeiGene and SpringWorks Announce Initiation of Phase 1 Clinical Trial of BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors GlobeNewswire
Feb-18-20 06:30AM	SpringWorks Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference GlobeNewswire +5.79%
Jan-13-20 06:00AM	Allogene Therapeutics and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate ALLO-715 in Combination with Nirogacestat in Multiple Myeloma GlobeNewswire
Jan-06-20 06:30AM	SpringWorks Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire -5.84%
Dec-16-19 04:38PM	Hedge Funds Have Never Been This Bullish On SpringWorks Therapeutics, Inc. (SWTX) Insider Monkey
Dec-13-19 10:07AM	We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth Simply Wall St.
Dec-09-19 10:00AM	Researchers Present Preclinical Data Showing Synergistic Activity of SpringWorks Therapeutics Gamma Secretase Inhibitor (Nirogacestat) with GlaxoSmithKlines BCMA Antibody-Drug Conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire +12.15%
Nov-12-19 08:00AM	SpringWorks Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
Oct-24-19 06:30AM	SpringWorks Therapeutics Announces Initiation of Phase 2b ReNeu Clinical Trial of Mirdametinib in Children and Adults with Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (NF1-PN) GlobeNewswire -5.73%
Sep-27-19 08:00PM	Beacon Roofing, Sunrun, Marchex and Other 13D Filings Barrons.com
Sep-24-19 06:30AM	European Commission Grants Orphan Drug Designation for Nirogacestat for the Treatment of Soft Tissue Sarcoma GlobeNewswire
Sep-17-19 04:05PM	SpringWorks Therapeutics Announces Closing Of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Sep-13-19 04:12PM	Cloudflare IPO Prices Above Range, Raises $525 Million Investor's Business Daily
Sep-12-19 06:15PM	SpringWorks Therapeutics Announces Pricing Of Initial Public Offering GlobeNewswire

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase IIb clinical trial for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in preclinical trials for the treatment of RRMM. In addition, it is developing Mirdametinib + lifirafenib, a combination therapy that is in Phase Ib clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience